2型糖尿病患者全膝关节置换术围术期使用非甾体抗炎药后术后心力衰竭发生率
单中心倾向匹配研究纳入2015至2023年3906例初次全膝关节置换术患者,发现围术期使用美洛昔康或塞来昔布者中,术前2型糖尿病诊断与术后心力衰竭显著相关(P=0.006);在2型糖尿病患者中,塞来昔布组术后心力衰竭发生率高于美洛昔康组(4.8% vs 2.2%,P=0.002)。
要点
- 围术期使用美洛昔康或塞来昔布时,2型糖尿病患者的术后心力衰竭发生率高于非糖尿病患者(P=0.006)。
- 2型糖尿病患者中,塞来昔布组术后心力衰竭发生率为4.8%,美洛昔康组为2.2%(P=0.002)。
- 作者主张在给2型糖尿病患者开具美洛昔康和塞来昔布时考虑新发心力衰竭风险。
核心结论
- 2型糖尿病患者围术期使用非甾体抗炎药后术后心力衰竭发生率高于非糖尿病患者。
- 2型糖尿病患者围术期使用塞来昔布时新发心力衰竭发生率高于使用美洛昔康。
研究设计与样本
- 单中心学术机构回顾性审查2015至2023年3906例初次全膝关节置换术患者。
- 收集人口学、术前2型糖尿病诊断、术后新发心力衰竭、围术期非甾体抗炎药使用及阿司匹林预防深静脉血栓等数据。
- 采用倾向匹配控制年龄、美国麻醉医师协会评分和阿司匹林使用。
- 用卡方分析比较2型糖尿病患者中美洛昔康与塞来昔布组的术后心力衰竭发生率。
主要发现
- 围术期使用美洛昔康或塞来昔布的患者中,术前2型糖尿病诊断与术后心力衰竭存在不成比例关联(P=0.006)。
- 2型糖尿病患者中,塞来昔布组术后心力衰竭发生率为4.8%,美洛昔康组为2.2%(P=0.002)。
关键数值与推荐
- 2型糖尿病患者围术期使用塞来昔布后术后心力衰竭发生率为4.8%。
- 2型糖尿病患者围术期使用美洛昔康后术后心力衰竭发生率为2.2%。
临床怎么用
- 作者主张在术后给2型糖尿病患者开具美洛昔康和塞来昔布时,考虑新发心力衰竭风险。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Nonsteroidal anti-inflammatory drugs (NSAIDs) can increase fluid retention and the risk of heart failure (HF). Type 2 diabetes mellitus (T2DM) is known to increase the risk of cardiac disease, including HF. As part of a modern multimodal pain protocol, NSAIDs are commonly used in total knee arthroplasty (TKA), but the risk of NSAID use in TKA for T2DM patients is not well understood. The purpose of this study was to compare rates of new-onset HF following TKA in type 2 diabetics with varying NSAID use. METHODS: We reviewed 3,906 patients who underwent primary TKA from 2015 to 2023 at a single academic institution. Data collected included demographics, preoperative diagnosis of T2DM, postoperative development of new-onset HF, NSAIDs taken perioperatively, and aspirin use for deep vein thrombosis prophylaxis. Propensity matching was conducted to control for age, American Society of Anesthesiologists score, and aspirin use. Rates of postoperative HF within T2DM patients who took meloxicam versus celecoxib were compared using Chi-square analyses. RESULTS: Among patients who took meloxicam or celecoxib perioperatively, a preoperative diagnosis of T2DM was disproportionately associated with postoperative HF (P = 0.006). When comparing peri-TKA use of meloxicam versus celecoxib in T2DM patients, the use of celecoxib was disproportionately associated with the development of postoperative HF (2.2% [meloxicam], 4.8% [celecoxib], P = 0.002). CONCLUSIONS: We found patients who had T2DM developed postoperative HF at higher rates than nondiabetics following peri-TKA NSAID use and that T2DM patients developed new-onset HF at higher rates when utilizing celecoxib than meloxicam in the peri-TKA period. Along with the many other factors that contribute to an orthopaedic surgeon's decision on which NSAID to use postoperatively, we advocate for consideration of the risk of new-onset HF in T2DM patients when prescribing meloxicam and celecoxib in the post-TKA period.
引用
- Antonioli SS, Richardson MA, Prinos A, et al. Rates of Postoperative Heart Failure Among Type 2 Diabetics With Use of Nonsteroidal Anti-Inflammatory Drugs for Total Knee Arthroplasty. J Arthroplasty. 2025. PMID: 40086643. doi:10.1016/j.arth.2025.03.015
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。